menu
Gene-Panel Sequencing and the Prediction of Cancer Risk
Gene-Panel Sequencing and the Prediction of Cancer Risk
Sanger sequencing, also known as the “chain termination method”, is a method for determining the nucleotide sequence of DNA. The method was developed by two time Sanger and his colleagues in 1977, hence the name the Sanger Sequence.

Gene-Panel Sequencing and the Prediction of Cancer Risk

Retrogen’s Clinical Laboratory Services are run under guidelinesregulated by the Clinical Laboratories Improvement Amendments (CLIA) and underaccreditation by the College of American Pathologist. Next-Gen and Sanger basedgenomics workflows have been optimized to provide industry leading quality andreliability. The DNA sequence of interest is used as a template for a special typeof PCR called chain-termination PCR. Chain-termination PCR works just likestandard plasmid preparation, but with one major difference: the addition of modifiednucleotides (dNTPs) called dideoxyribonucleotides (ddNTPs). In the extensionstep of standard PCR, DNA polymerase adds dNTPs to a growing DNA strand bycatalyzing the formation of a phosphodiester bond between the free 3’-OH groupof the last nucleotide and the 5’-phosphate of the next.